echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Analysis of China's pharmaceutical foreign trade to Central Asia from January to August this year

    Analysis of China's pharmaceutical foreign trade to Central Asia from January to August this year

    • Last Update: 2013-10-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: medical network 2013-10-25 since the establishment of diplomatic relations between China and the five Central Asian countries in 1992, the commodity trade between China and the Central Asian region has grown rapidly The trade volume increased from 460 million US dollars in 1992 to 45.94 billion US dollars in 2012, an increase of nearly 100 times Our country is rapidly becoming the number one trading partner of all Central Asian countries China's pharmaceutical trade with Central Asia also grew rapidly In 2012, the trade volume reached 229 million US dollars, and the export volume alone reached 176 million US dollars, of which the export volume of Western medicine products reached 90.27 million US dollars From January to August 2013, China's pharmaceutical trade to Central Asia reached US $161 million, a year-on-year increase of 10.01%; and its export reached US $123 million, a year-on-year increase of 6.28% Among them, the export of Western medicine products reached US $66.15 million, up 10.68% year on year There are two peaks of growth in the pharmaceutical trade between China and Central Asia Central Asia is also one of the important export destinations of pharmaceutical products, with the export volume accounting for more than 76% of the total trade volume Since 2008, China's pharmaceutical export to Central Asia has shown a sustained growth trend, in which there have been two peaks, respectively in 2008 and 2011 For quite a long time after the independence of the five Central Asian countries, their own industrial system was paralyzed, the pharmaceutical industry was relatively backward, and the production capacity of medical equipment was almost zero Therefore, there was a strong demand for Chinese medical products, plus 2003 In 2008, the Ministry of Commerce started to hold China Commodity Exhibition in Kazakhstan, and Chinese pharmaceutical enterprises such as Beijing Shuanghe Pharmaceutical Co., Ltd and Shenzhen Mindray started to explore the Central Asian market In 2008, the growth of China's pharmaceutical exports to Central Asia reached the first peak: the year-on-year growth rate reached 32.36% However, in 2009 and 2010, due to the impact of the global financial crisis, China's pharmaceutical trade with Central Asia was affected, and the export growth dropped significantly In 2011, China's economy became the engine of the world economy The pharmaceutical trade between China and Central Asia came out of the haze of the international financial crisis The export trade reached the second growth peak: the year-on-year growth rate reached 32.34%, almost the same as that in 2008 However, with the downturn of global economic situation and the increase of uncertain factors in 2012, the growth rate of China's pharmaceutical export to Central Asia slowed down China's exports of Western medicine products to Central Asia always account for half of China's exports to Central Asia, accounting for no less than 50% In the ups and downs of pharmaceutical exports, the export growth of Western medicine products also reached two growth peaks of 29.44% in 2008 and 28.28% in 2011 In 2013, the growth of China's pharmaceutical exports to Central Asia remained at a relatively low level, but from June, the dawn of growth began to appear The amount of pharmaceutical exports rebounded from the previous negative growth to a positive growth of about 20%, and the growth rate of Western medicine exports also climbed to a high of 54.73% in July From January to August 2013, the export of Western medicine products to Central Asia was mainly concentrated in Uzbekistan and Kazakhstan, accounting for us $34.25 million and US $19.34 million respectively, accounting for 51.78% and 29.24% respectively, with a year-on-year growth rate of 26.31% and 15.84% respectively Under the condition of negative growth of exports to Kyrgyzstan and Turkmenistan and slight growth of exports to Tajikistan, it has made great contribution to the recovery of overall export growth of Western medicine commodities to Central Asia Among the western medicine commodities I export to Central Asia, "troika" - raw materials, western medicine preparations and biochemical drugs are almost equal Among them, the proportion of APIs is slightly higher than 1 / 3, mainly including other Western medicine raw materials, penicillins, cephalosporins and amino acids; the proportion of Western medicine preparations is about 1 / 3, and other Western patent medicines, cephalosporins and penicillins become the top three preparations for export; the proportion of biochemical drugs is slightly lower than 1 / 3 According to the export customs code, the western medicine varieties with large export volume are the most prominent among the preparations and peptone derivatives with fixed dosage, which are all over US $10 million, accounting for 44% of the total export volume of Western medicine, with export growth rates of 14.01% and 35.56% respectively; active yeast, organic sulfide and citric acid are the second, with export volume of more than US $2 million From January to August 2013, China's export of Western medicine to Central Asia was in the trend of rising in volume and falling in price, which was the opposite of the situation of falling in volume and rising in price Specifically, in addition to the fact that the export volume and price of biochemical drugs have risen a little, the export prices of APIs and Western medicine preparations have both dropped by more than 15%, while the export volume has risen by more than 25% However, this situation is mainly affected by the decline in exports in the first half of the year, and has changed since June From January to August 2013, China's export mode of Western medicine to Central Asia was mainly general trade, accounting for more than 98% Shandong, Hebei and Xinjiang are among the top three export provinces, with the export volume exceeding 9 million US dollars Among them, Shandong's export volume reached 14.82 million US dollars, an increase of 35.49% year on year From January to August 2013, China's 304 enterprises engaged in the export of Western medicine products to Central Asia, with private enterprises and state-owned enterprises showing strong performance, with the export volume of US $36.86 million and US $20.78 million respectively Angel yeast Co., Ltd., Linyi Shansong Biological Products Co., Ltd., Qingdao xinjiahua import and Export Co., Ltd and Shandong Jiahua Health Products Co., Ltd all exported more than US $3 million to Central Asia western medicine, of which the export growth rate of the latter three companies reached more than 45% year-on-year The future development is full of hope In the past decade, China's good political relations, convenient geographical conditions and strong economic complementarity with Central Asian countries have made a qualitative leap in bilateral economic and trade relations The improvement of the overall economic situation of the Central Asian countries, the improvement of the level of cooperation between the two sides and the optimization of the trade structure further promote the commodity trade between China and the Central Asian region As China's close neighbor to the west, there is a silk road in history Central Asia has become an important partner in China's commodity trade China's trade relationship with the five Central Asian countries has become increasingly close, and plays an increasingly important role in the economic development of Central Asia China has become the largest trading partner of Kazakhstan and Turkmenistan, the second largest trading partner of Uzbekistan and Kyrgyzstan, and the third largest trading partner of Tajikistan However, adverse factors still exist, mainly in three aspects: first, the political situation in Central Asia is unstable For a long time, the development of the five Central Asian countries known as the "broken zone" by western scholars has been influenced by the United States, Russia and the European Union At the same time, the continuous unrest in Afghanistan, the prevalence of religious extremism and the rampant terrorist activities of "East Turks" have all had a negative impact on the trade between China and Central Asia Second, the market competition in Central Asia has intensified Russia has always been the most important trade partner of Central Asian countries, and has a dominant position in the Central Asian market In 2010, the establishment of the tariff union of Kazakhstan, Belarus and Russia opened a convenient door for the commodity trade between Russia and Central Asia It can be said that Russia is China's most powerful rival in the Central Asian market Third, there are many trade-related restrictions in Central Asian countries For example, there are many restrictions on Haiguan, serious corruption, relatively closed medical market, and language communication barriers, which have formed certain resistance for Chinese enterprises to explore the market in Central Asia In recent years, the Central Asian countries have entered the stage of steady and rapid economic growth, and the demand for trade and investment has continued to grow However, China's investment in Central Asia has continued to expand, and the investment field has continued to expand The cooperation between the two sides in medicine, transportation, agriculture, high and new technology and other fields is still in its infancy, with huge development potential The pharmaceutical industry in Central Asia has a weak foundation, and the production of pharmaceutical products is in short supply Due to the limited payment capacity of the government and the people, there is less demand for high-end pharmaceutical products Therefore, China's relatively low-cost basic pharmaceutical products have great potential in the pharmaceutical market in Central Asia Russia, as the main competitor, lags behind China in the development of medicine and other fields, which makes it difficult to compete with Chinese pharmaceutical companies in the Central Asian market In March this year, Tajikistan officially became a member of the world trade organization, while Kazakhstan expects to complete the WTO accession negotiations by the end of this year This indicates that tariff barriers to foreign trade in medicine with Central Asian countries will be reduced Since June this year, China's export of Western medicine to Central Asia has once again entered the fast lane of growth Silk Road Economic Belt is China's background for president Xi Jinping's visit to China in September We can expect that more and more Chinese pharmaceutical enterprises will go to the Central Asian region to open up markets and invest in medicine The third peaks of medical exports will be coming As a top priority among priorities for medical exports in Central Asia, western medicine exports are expected to be " Higher up ".
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.